Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 14, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

Results from this short clinical pharmacology trial inform and support further clinical development of ensifentrine as an add-on to dual and triple COPD therapy Investment community conference call...
January 09, 2019 08:00 ET | Source: Verona Pharma plc

Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554

LONDON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative...
January 03, 2019 02:00 ET | Source: Verona Pharma plc

Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

LONDON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative...
December 17, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD

LONDON, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing...
November 06, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018

Initiated a Phase 2 trial of RPL554 as add-on to dual bronchodilator therapy for COPD maintenance treatment; enrolled last patient and dosing underway Progressed DPI and pMDI programs; formulations...
October 31, 2018 03:00 ET | Source: Verona Pharma plc

Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

Enrollment complete ahead of schedule Top line data expected in January 2019 LONDON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a...
October 30, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update

LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
October 26, 2018 05:12 ET | Source: Verona Pharma plc

Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference

Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants Phase 2a results demonstrate RPL554 has favorable pharmacokinetic and pharmacodynamic profile in cystic fibrosis...
September 27, 2018 02:00 ET | Source: Verona Pharma plc

Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018

LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
September 20, 2018 11:49 ET | Source: Verona Pharma plc

Issue of Shares & PDMR Announcement

LONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...